Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016)
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016)
Authors
Keywords
HER2-positive, Metastatic breast cancer, Trastuzumab, HER2-targeted therapy, Long-term survival, Population-based
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 171, Issue 1, Pages 151-159
Publisher
Springer Nature
Online
2018-05-08
DOI
10.1007/s10549-018-4804-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001–2016)
- (2018) Benjamin Daniels et al. BREAST
- Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort
- (2017) Benjamin Daniels et al. BMJ Open
- Clinical predictors of long-term survival in HER2-positive metastatic breast cancer
- (2016) Pooja Murthy et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer
- (2016) K. Harano et al. BREAST CANCER RESEARCH AND TREATMENT
- Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab
- (2015) B. Yeo et al. BREAST
- Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA
- (2015) J.-P. Spano et al. BREAST
- Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time
- (2015) S. Hieke et al. CLINICAL CANCER RESEARCH
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
- (2014) Isabell Witzel et al. BMC CANCER
- Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
- (2014) D A Yardley et al. BRITISH JOURNAL OF CANCER
- Rising cost of anticancer drugs in Australia
- (2014) D. J. Karikios et al. INTERNAL MEDICINE JOURNAL
- The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy
- (2014) Angelo Gámez-Pozo et al. PLoS One
- Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study
- (2013) Ines Vaz-Luis et al. Clinical Breast Cancer
- Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
- (2012) Thuy Vu et al. Frontiers in Oncology
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started